Purpose: This study explored whether complement factor 3 (C3) in plasma is associated with incidence of diabetes in a population-based cohort. We also identified genetic variants related to C3 and explored whether C3 and diabetes share common genetic determinants.
C omplement factor 3 (C3) is a central component of the complement system of the innate immune defense (1) . It is essential for the activation of all three complement pathways, that is, the classical, alternative, and lectin pathways (2) . The synthesis of C3 occurs primarily in the liver (3), but C3 is also expressed and produced in human adipose tissue (4) . Recent studies suggest that complement activation also has intracellular functions that might be of broad physiological significance (5, 6) . C3 is an acute phase reactant, and elevated plasma levels are seen in response to inflammation and infection, whereas decreased levels are detected in immune complex deposition (7) . Complement factor H (CFH) is an important inhibitor of C3 activation (8) , and a genome-wide association study (GWAS) of an Asian population reported significant relationships between C3 levels and polymorphisms in the CFH gene (9) .
Several studies suggest that C3 could have a role in development of cardiometabolic diseases (1) . Elevated levels of C3 in plasma have been associated with obesity and weight gain (4, 10) , hypertension (11) , insulin resistance (12) , and the metabolic syndrome (13) . C3 has also been associated with incidence of diabetes in prospective studies (10, 14) . It has been proposed that acylation-stimulating protein, (i.e., C3a), which is generated during proteolytic cleavage of C3, could have insulin-like effects and thereby partly explain the association between C3 and diabetes (15, 16) .
We hypothesized that there could be a causal relationship between C3 in plasma and incidence of diabetes. Therefore, we explored the relationship between C3 and diabetes in a study from the general population and used genetic polymorphisms as instrumental variables. First, we replicated the relationship between C3 in plasma and increased incidence of diabetes in a large population-based cohort. Second, we performed a GWAS to identify genetic loci associated with C3 plasma levels. In the next step, genetic polymorphisms associated with C3 were tested for their relationships with diabetes, using a well-powered publically available database of genetic polymorphisms in diabetes cases and controls. Finally, we performed a replication of the relationship between C3 and a genetic locus, which was shared between the C3 and diabetes phenotypes.
Material and Methods
The population-based cohort Malmö Diet and Cancer Study (MDC), from the city of Malmö in southern Sweden, was recruited during the period March 1991 to September 1996 (17). A random subsample of participants recruited between October 1991 and February 1994 were invited to a substudy of cardiovascular disease; the MDC cardiovascular cohort (MDC-CC; n = 6103) (18). Out of these, 5533 subjects agreed to give fasting blood samples, which were stored in 280°C for later analysis. To investigate the relationship between C3 levels in plasma and incidence of diabetes during the follow-up, individuals with missing values of covariates, as well as those with diabetes at baseline (i.e., self-reported diabetes or antidiabetic drug treatment, fasting whole blood glucose of $6.1 mmol/L, or diabetes according to national or local patient registers), were excluded from the study. The final study population included 4368 individuals (aged 46 to 68 years, 60.7% women). For GWAS, we included subjects with information about C3 plasma levels and genotyping data (n = 4188).
Baseline examinations
Information on current use of lipid-lowering, blood pressurelowering, or antidiabetic medications, smoking habits, leisure time physical activity, and educational level were obtained from a self-administered questionnaire at baseline. Participants were classified into three categories of smoking habits: current smokers (regular and occasional), former smokers, and never smokers. Low level of leisure time physical activity was defined as the lowest quartile of a score revealed through 18 questions covering a range of activities in the four seasons. The measurements for waist circumference (in cm) were carried out midway between the lowest rib margin and the iliac crest. Blood pressure (mm Hg) was measured using a mercury-column sphygmomanometer after 10 minutes of rest in the supine position. Education was divided into three categories: ,9, 9 to 12, and .12 years of education and low level of education was defined as ,9 years of education.
Blood glucose and hemoglobin A1c (HbA 1c ) were analyzed from fasting blood samples following standardized procedures at the laboratory of the university hospital. Insulin was measured by a radioimmunoassay in mIU/L and the updated homeostatic model assessment version 2 (HOMA2) index was calculated (19). Because measurements of glucose in whole blood give lower concentrations than analysis of glucose in plasma, a conversion factor of 1.15 was applied when calculating the HOMA2 values (20). High-density lipoprotein (HDL) cholesterol was measured in fresh blood samples. C-reactive protein (CRP) in plasma was analyzed using the Tina-quant CRP latex assay (Roche Diagnostics, Basel, Switzerland).
C3 was analyzed in plasma samples, which were separated within 1 hour after venipuncture and stored in 280°C. C3 was analyzed with an immunoturbidimetric method using Cobas c-systems and reagents from Roche Diagnostics (Mannheim, Germany). The target range was 0.04 to 5 g/L. The reference value according to the manufacturer was 0.9 to 1.8 g/L. Interassay and intra-assay coefficients of variation were 2.0% and 1.3%, respectively.
Follow-up and end-point definition
All participants in the study were followed from the baseline examinations until first diagnosis of diabetes, emigration from Sweden, death, or end of follow-up (31 December 2012). Incident cases of diabetes in the cohort were gathered from different sources, which have been described in detail in other studies (21). In short, incidence of diabetes was identified by using the Malmö HbA 1c register, the Swedish National Diabetes Register, the Swedish inpatient register, the Swedish outpatient register, the nationwide Swedish drug prescription register, and the regional Diabetes 2000 register of the Skåne region (21).
Genotyping
Nonfasting blood samples were drawn at the baseline examination and stored in the biobank at 280°C. Genotyping was performed using the Illumina HumanOmniExpressExome BeadChip, the iScan system, and the Autocall calling algorithm (Illumina, San Diego, CA). The array includes .700,000 single nucleotide variations with genome-wide coverage of common genetic variation (http://www.illumina.com/). All procedures followed the standard protocol.
Genotyping quality control
Quality control was performed by exclusion of missingness . 0.05 (both individual and marker); identity-by-descent match; heterozygosity (absolute cryptic relatedness inbreeding coefficient . 0.2); sex mismatch; population outliers based on inspection of the first two principal components and Hardy-Weinberg equilibrium (P , 10 26 ). Minor allele frequency limit was 0.01. A total of 613,160 SNPs were included in the analysis. The quantile-quantile plot shows no population stratification (Supplemental Fig. 1 , median genomic inflation factor = 0.998).
In silico look-up in Diabetes Genetics Replication and Meta-Analysis and glucose kinase regulatory protein gene variants replication in the European Genetic Database cohort Because the statistical power for comparing incidence of diabetes in relationship to genetic polymorphisms is limited in MDC-CC, we performed an in silico look-up in Diabetes Genetics Replication and Meta-Analysis (DIAGRAM; http:// diagram-consortium.org/index.html). The top SNPs of all independent loci that were associated with C3 at P , 10
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were tested for association with diabetes in DIAGRAM (22). The DIAGRAM is a publically available study of genetic variants and diabetes, which includes 12,171 cases and 56,862 controls of European ancestry (DIAGRAM v3 GWAS) and a cohort of 26,488 cases and 83,964 controls of European, South Asian, Mexican, and East Asian ancestry (DIAGRAM transethnic GWAS).
The top variant in the glucose kinase regulatory protein (GCKR) gene [and two variants in linkage disequilibrium (LD) with this variant] were replicated using healthy control subjects from the Radboud University Medical Center (Nijmegen, The Netherlands) and the University of Cologne (Cologne, Germany) (n = 946). The participants were enrolled between 2008 and 2010, as control subjects in the European Genetic Database (EUGENDA; www.eugenda.org), a multicenter database for the clinical and molecular analysis of age-related macular degeneration. C3 measurements were determined from serum samples, prepared by coagulation at room temperature. After centrifugation, samples were stored at 280°C within 1 hour after collection. C3 was measured in serum samples by radial immunodiffusion (or Mancini method) using mono-specific polyclonal rabbit antisera as described previously (23, 24). All measurements were performed in a single assay. Genomic DNA was extracted from peripheral blood samples using standard procedures, and genotyping was performed using a custom-modified HumanCoreExome array by Illumina (25) .
Statistical analysis

Incidence of diabetes in relationship to C3
Subjects were categorized into sex-specific quartiles of C3. The cross-sectional relationship of C3 quartiles and diabetes risk factors was assessed using one-way analysis of variance (continuous variables) and a Pearson x 2 (dichotomous variables). Multiple linear regression was used to assess the association between C3 (dependent variable) and glucose, HbA 1c , HOMA2, and insulin, respectively, adjusted for potential confounding factors. C3, CRP, HOMA2, and insulin were natural log-transformed before analysis.
Cox proportional hazards regression was used to examine hazard ratios (HRs) with 95% confidence interval (CI) for incidence of diabetes by quartiles of C3, using the lowest quartile as the reference category. The P for trends across quartiles was obtained by modeling the quartiles as an ordinal variable. Possible interactions between C3 and other risk factors for diabetes were investigated by introducing interaction terms in the fully adjusted multivariable model. The fit of the proportional hazards model was confirmed by plotting the incidence rate over time. The Kaplan-Meier curve was used to illustrate incidence of diabetes in relationship to C3. Time axis was follow-up time until death, emigration, incident diabetes, or end of follow-up. Model discrimination was estimated with Harrell's C-statistics. SPSS Statistics (version 22) and Stata software version 12.0 (Stata Corp, College Station, TX) were used for statistical analyses in the MDC-CC.
GWAS of C3
For GWAS, linear regression models were used to test the association between genetic variants and natural logtransformed C3 adjusting for age and sex, assuming an additive genetic model. A P of ,5 3 10 28 was considered as genome-wide significant, corresponding to a Bonferroni correction for 1 million tests. Version 1.07 of PLINK software (http://pngu.mgh.harvard. edu/purcell/plink/) was used for association analyses and quality control. Manhattan plots and quantile-quantile plots were drawn with the R software version 3.1.2. Regional significance plots were drawn using LocusZoom (http://locuszoom.sph. umich.edu/locuszoom/). LD was assessed using the Pearson correlation coefficient (r 2 ) and checked using SNP Annotation and Proxy Search in 1000 genomes with CEU population panel (https:// www.broadinstitute.org/mpg/snap/ldsearch.php).
C3 and GCKR replication and meta-analysis
A linear regression analysis of the natural log-transformed C3 was performed using a linear Wald test as implemented in the EPACTS software (http://www.sph.umich.edu/csg/kang/ epacts/index.html). The analysis assumed an additive genetic model, included only individuals of European descent, and was adjusted for age, sex, and the first two ancestry principal components. Meta-analysis combining test statistics and standard errors (SEs) of the discovery and the replication cohort was performed using METAL software (http://csg.sph.umich.edu// abecasis/metal/).
Genetic polymorphisms and diabetes
We examined the top SNPs from the C3 GWAS for their associations with type 2 diabetes in DIAGRAM, a large publicly available database (22). We also performed instrumental variable analysis in MDC-CC, using two-stage methods in Stata version 12.0 (26). The SNPs that were genome-wide significant were used as instrumental variables for C3 to study incidence of diabetes. Among the SNPs that were in LD at the same loci, the SNP with the lowest P value was used.
The study was performed in accordance with the Declaration of Helsinki. The Ethics Committee at Lund University approved the MDC study (LU 51/90), and all participants provided informed written consent. The replication study was approved by the local ethics committee of the University Hospitals in Cologne and Nijmegen.
Results
Baseline characteristics
Baseline characteristics of the MDC-CC study population are presented in Table 1 , by quartiles of C3. Levels of C3 were associated with age, waist circumference, systolic blood pressure, use of antihypertensive or lipidlowering medication, CRP, smoking, low HDL cholesterol, low physical activity, and low educational level. HbA 1c , glucose, HOMA2, and insulin were positively and significantly associated with C3 levels, also after adjustment for possible confounding factors ( Table 2) .
Incidence of diabetes in relationship to C3
A total of 538 (12.3%) subjects developed diabetes during a mean follow-up of 17.7 6 4.4 years. Subjects in the 4th compared with the 1st quartile of C3 had significantly higher incidence of diabetes (Fig. 1) . The HR remained significant after adjustment for possible confounders in model 2 (HR, 1.60; 95% CI, 1.19 to 2.15; P = 0.001). The result remained similar after additional adjustment of CRP [HR, 1.54 (1.13 to 2.09); P = 0.005) ( Table 3) ]. There was no significant interaction between C3 and sex, age, or waist, respectively, with regard to incidence of diabetes.
The C-statistics value for model 2 was 0.7803 (95% CI, 0.7616 to 0.7990) and increased significantly to 0.7834 (0.7648 to 0.8021) when C3 was added to the model [difference in C-statistics, 0.0031; 95% CI, 0.0001 to 0.0061; P = 0.043]. The C-statistics value for model 3 (i.e., including CRP) was 0.7822 (0.7636 to 0.8008) and increased to 0.7841 (0.7655 to 0.8027) when C3 was added to the model (difference in C-statistics, 0.0019; P = 0.145).
GWAS of C3
Five variants in LD on chromosome 1 at the CFH gene showed a genome-wide significant association with C3 levels, after adjusting for age and sex ( Fig. 2 ; Supplemental Table 1 ). The lead SNP was rs12405238, an intronic variant (minor allele T, minor allele frequency = 0.23, b = 20.03, P = 9.64 3 10 210 ). Regional significance plots for the significant variants on chromosome 1 at the CFH locus are presented in Supplemental Fig. 2 . SNPs that showed a suggestive association with C3 levels at P , 10 25 are listed in Supplemental Table 1 . Insulin, median (P25-P75) a (n = 4326) 5.00 (3.00-6.00) 6.00 (4.00-8.00) 7.00 (5.00-9.00) 8.00 (6.00-12.00) 1.35 3 10
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Median (P25-P75) are presented for CRP, insulin, and HOMA2. All other values are means 6 standard deviation or percentages. P values were calculated using analysis of variance (1 degree of freedom) for continuous variables and a Pearson x 2 for percentages.
a P value for ln transformed value. These loci were located in or close to the genes CFB, NNT-AS1, and GCKR (Supplemental Table 1 ).
Genetic polymorphisms and diabetes
Individuals carrying the minor allele of the lead SNP in the CFH gene (rs12405238) had a lower level of C3 (Supplemental Table 2 ). However, there was no significant association between rs12405238 and diabetes in DIAGRAM (P = 0.98). Furthermore, there was no relationship between rs12405238 and glucose, insulin, HbA 1c , or incidence of diabetes in MDC-CC (Supplemental Table 3 ). The association using this SNP as an instrumental variable was nonsignificant for incidence of diabetes (P = 0.330), glucose (P = 0.721), HbA 1c (P = 0.207), HOMA2 (P = 0.597), and insulin (P = 0.537).
To explore potential associations with diabetes among loci that did not reach the genome-wide significance level (P , 5 3 10 28 ) for the association with C3, we also explored loci suggestive for association with P , 10 25 . The top variant in the GCKR gene (rs780094) was associated with diabetes, both in the European (OR, 1.04; 95% CI, 1.00 to 1.08) (P = 0.025) and transethnic DIAGRAM GWAS (P = 1 3 10 25 ) (Supplemental Table 1 ). The association using rs780094 as an instrumental variable in MDC-CC was nonsignificant for glucose (P = 0.058) and for incidence of diabetes (P = 0.705). The rs780094 SNP was significantly associated with C3 also after adjustments of glucose and insulin (P = 3.01 3 10 28 ).
Replication of C3 and polymorphisms in the GCKR gene The relationship between plasma C3 and rs780094 was confirmed in the replication cohort of control subjects from EUGENDA (P = 0.02301; b 6 SE, 0.0218 6 0.0096). After a meta-analysis, the association of rs780094 achieved a higher level of significance (P =1.33 3 10 27 ; b 6 SE, 0.0232 6 0.0044). One of the SNPs in high LD, rs1260326, achieved an even stronger level of significance (P = 6.30 3 10
28
). The results from a meta-analysis are shown in Table 4 .
Discussion
The current study showed that increased C3 in plasma is a risk marker for developing diabetes among middle-aged subjects, after taking potential confounders into account. Studies of genetic determinants of C3 levels could provide knowledge of the pathway and functional mechanisms of C3 and be useful in identifying individuals at high risk. The GWAS of C3 identified one region at the CFH gene on chromosome 1, which was associated with C3 levels in blood. This locus was also identified in a study of an Asian population (9) . The CFH gene encodes CFH, a major inhibitor of C3 activation via the complement cascade (8) . When factor H is functionally impaired or absent, levels of C3 decrease due to spontaneous, uncontrolled activation of the alternative pathways in which C3 is the central component (27) (28) (29) . However, even though polymorphisms at the CFH locus were strongly associated with C3 levels in plasma, there was no relationship between the CFH locus and glucose, HbA 1c , insulin, or incidence of diabetes in our study. Nor were there any significant relationships between the rs12405238 polymorphism and diabetes in the DIAGRAM cohort, which is a case control set with good statistical power. This suggests that the relationship between plasma C3 and diabetes might not be causal. However, whereas factor H regulates C3 levels in blood, it could not do so inside the living cells, so there could still be a role for intracellular C3 in the development of diabetes (30) . Of the other eight loci associated with C3 with P , 10
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, the GCKR locus has previously been linked to glucose metabolism, diabetes, and metabolic traits (31, 32) . The gene product of GCKR is a regulatory protein that inhibits glucokinase, which catalyzes the conversion of glucose to glucose-6-phosphate and is a key regulator of glucose homeostasis (33) . The P value for the relationship between rs780094 and C3 was 2.0 3 10 26 in MDC-CC and 0.023 in the replication cohort. The results were similar for rs1260326, a nonsynonymous variant in LD with rs780094, which is thought to influence the glucose metabolism (33) . The relationship between rs780094 polymorphisms and C3 was unchanged by adjustments for glucose or insulin, which implicates that glucose is not a mediating link between rs780094 and C3. It is also noteworthy that GCKR has been associated with concentration of CRP and several cardiometabolic traits in previous genetic studies (34, 35) . Hence, it seems likely that the relationship between C3 and incidence of diabetes at least partly could be explained by common genetic factors associated with diabetes as well as C3. Previous studies have reported that various inflammation markers, for example, acute-phase proteins and leukocyte levels are associated with diabetes (36, 37) . The effect size was quite strong in this study, with an HR of 3.5 in the 4th quartile of C3 after adjustment for age and sex, and 1.54 after adjustments for risk factors, including CRP. Overall, this is in accordance with previous studies of C3 and incidence of diabetes (14) . When both CRP and C3 were included in the multivariate model, C3 was significantly associated with diabetes, but CRP was not (P = 0.368). This is in accordance with previous studies suggesting that C3 may be a better marker of cardiometabolic traits than CRP (12, 38) . In accordance with previous studies, C3 levels were associated with increased waist circumference (4, 10, 39) . Synthesis of C3 occurs in small amounts in adipose tissue (4, 40) . Obesity is also one of the major risk factors for diabetes (4, 10) . In the current study adjustments were done for waist circumference to rule out any potential confounding due to obesity. However, the significant association between C3 and incidence of diabetes remained after adjustments for waist circumference and other risk factors.
Strengths and limitations
The data used for this study were derived from a large population-based cohort with long follow-up and many incident diabetes cases. The MDC-CC is an ethnically homogeneous population, which is important for a GWAS study. New events of diabetes were identified from several independent sources with good case validity. One limitation is lack of information on type of diabetes. The participants in the current study were 45 to 68 years old at baseline. Because type 1 diabetes usually develops earlier in the life, and prevalent cases of diabetes were excluded at the baseline examination, one can assume that almost all incident cases were type 2 diabetes. Another limitation could be that all information was collected at baseline and we have no information about change of exposure during the follow-up. However, a study showed that C3 levels change little during lifetime (7). The lead SNP was located in the CFH gene, a major regulator of C3. Hypothetically, there could be other pathways linking CFH and diabetes besides its effects on C3, which could counterbalance the effects on diabetes. The lead SNP rs12405238 showed a rather strong association with C3 (F statistics = 36), so the statistical power should be adequate for continuous traits, such as glucose. The genetic association with diabetes was primarily studied in DIAGRAM, which is a case control set with very good statistical power (41) . However, even though the results suggest that C3 in plasma is not a causal risk factor for diabetes, this cannot be completely ruled out.
In conclusion, plasma concentration of C3 is a risk marker for incidence of diabetes. We identified five SNPs at the CFH locus that are associated with C3 in a GWAS study. However, there was no relationship between the CFH locus and diabetes. The results suggest that the associations between plasma C3 and diabetes could, in part, be explained by pleiotropic effects related to the GCKR gene. 
